Related Experiment Video

Updated: Aug 12, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

[Left ventricular hypertrophy in patients with nephrogenic arterial hypertension]

A I Diadyk, A E Bagriĭ, A N Mitrofanov

    Likars'Ka Sprava
    |July 1, 1994
    PubMed

    Insights

    Hypertrophy of the left ventricle of the heart (HLVH) affects 30.2% of patients with chronic glomerulonephritis and hypertension. HLVH incidence increases with hypertension severity and duration, but geometric patterns are not associated with kidney function.

    Area of Science:

    • Cardiology
    • Nephrology
    • Medical Imaging

    Context:

    • Chronic glomerulonephritis (ChGN) often coexists with arterial hypertension (AH).
    • Left ventricular hypertrophy (LVH) is a known complication of AH.
    • Understanding LVH in ChGN patients with preserved or early renal insufficiency is crucial.

    Purpose:

    • To investigate the incidence and geometric characteristics of left ventricular hypertrophy (HLVH) in patients with ChGN and AH.
    • To determine correlations between HLVH and clinical factors including AH severity, duration, and renal function.

    Summary:

    • Echocardiography in 86 ChGN patients with AH revealed HLVH in 30.2%.
    • Concentric (80.8%) and symmetric (76%) patterns predominated.
    • HLVH incidence correlated positively with AH degree and duration, but not with sex, ChGN variant, or renal function.

    Impact:

    • Identifies a significant prevalence of HLVH in this patient cohort.
    • Highlights the impact of arterial hypertension on cardiac remodeling in chronic kidney disease.
    • Informs clinical management strategies for hypertensive ChGN patients.

    More Related Videos

    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

    Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

    Published on: January 20, 2023

    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

    Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

    Published on: June 27, 2025

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Mitral Regurgitation I: Introduction01:20

    Mitral Regurgitation I: Introduction

    Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Hypertension II: Pathophysiology01:29

    Hypertension II: Pathophysiology

    Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...